GlassScriptPhysician profile
Margaret Hicks
NPI 1306024492
$3,437.13
in general payments reported to CMS, 2019-2025
24 companies · $772 in 2025
The $772 reported for 2025 was more than what 93% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $444 · 2022: $805 · 2023: $743 · 2024: $673 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.95 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $581.15 | 2021-2025 | |
| Astellas Pharma US INC | $481.51 | 2023-2025 | Veozah |
| Biogen, INC. | $287.24 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $267.23 | 2021-2023 | |
| Evofem Biosciences, INC. | $259.66 | 2021-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $233.62 | 2021-2024 | |
| Organon LLC | $188.54 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $180.00 | 2023 | Myfembree |
| Myovant Sciences INC. | $167.95 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.73 | 2022-2024 | |
| Shield Therapeutics INC | $96.92 | 2023-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $93.19 | 2021-2023 | Gardasil 9 |
| Hologic Sales and Service, LLC | $84.10 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Myriad Women'S Health, INC. | $75.36 | 2023 | Myrisk |
| Amgen INC. | $69.85 | 2023-2024 | Prolia, Evenity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $63.01 | 2021-2023 | Saxenda, Wegovy |
| Therapeuticsmd, INC. | $35.97 | 2022 | |
| Mylan Pharmaceuticals INC. | $30.47 | 2022 | |
| Ethicon US, LLC | $24.65 | 2022 | |
| Millicent US INC | $23.10 | 2025 | Femlyv, Intrarosa |
| Smith+Nephew, INC. | $19.11 | 2025 | Stravix |
| Urovant Sciences INC | $18.60 | 2021 | |
| Exeltis, USA INC. | $17.50 | 2025 | Slynd |
| Scynexis, INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.